<!doctype html><html lang=zh-tw><head><meta charset=utf-8><meta name=description content="H1 { font-size: 150px; font-weight: 900; }  Coagultaion Testing  林協霆 2023.05.31
 Overview of Hemostasis primary hemostasis 初級止血 secondary hemostasis 二級止血  primary hemostasis 初級止血  血小板的正常功能 : 👮監測血管內皮的完整性並在血管損傷部位形成栓塞以阻止和防止血液滲漏到血管外 沒有血管損傷 : 前列環素（prostaglandin）和內皮細胞分泌的一氧化氮的抑制🔐 血管損傷和內皮損傷  交感神經系統被啟動並引起血管收縮 collagen, fibronectin, and laminin : exposed to circulating blood 👷血小板附在暴露的內皮下基質蛋白上，開始止血栓形成過程     secretion of storage granule content  血小板顆粒 : 含有數千種蛋白質，啟動後釋放 3 major secretory granules  alpha-granules  凝血因子（I、II、V 和 XI）、 fibrinolysis system components coagulation inhibitors complement components (C1 inhibitor, C3, and C4)   delta-granules  ADP   lysosomes     during platelet activation 血小板活化  （ADP、thromboxane A2）啟動信號通路，將 GPIIb/IIIa 轉化為 divalent fibrinogen fibrinogen 👉 聚集/凝聚  platelet aggregation 血小板聚集  GPIIb/IIIa  募集額外的血小板   transmembrane ADP receptors P2Y1 and P2Y12  血小板形態學變化 血小板聚集     secondary hemostasis 二級止血  沒流血時：  inactive precursor enzymes (zymogens) 在血漿中循環   流血時：  導致fibrin polymerization和血小板活化， 形成clot   2 個途徑 :  extrinsic intrinsic       Coagulation Factor - I  I - fibrinogen II - prothrombin   III - tissue thromboplastin (tissue factor)   IV - ionized calcium ( Ca++ ) V - labile factor or proaccelerin   PL : platelet membrane phospholipid   VII - stable factor or proconvertin   Coagulation Factor - II VIII - antihemophilic factor IX - plasma thromboplastin component, Christmas factor X - Stuart-Prower factor XI - plasma thromboplastin antecedent XII - Hageman factor   XIII - fibrin-stabilizing factor   Extrinsic pathway  血管損傷或單核細胞啟動導致 VII（VIIa）啟動 啟動 IX (intrinsic）和 X（common）  Intrinsic pathway  由 XII 轉化為 XIIa 開始 XI 和 IX 逐步轉化為其活性形式 VIIIa （由thrombin啟動）  在活化的血小板表面作為 IXa 的Cofactor 促進 X to Xa     然後兩條路徑匯聚到Common Pathwya共同路徑  X啟動為Xa Xa 將prothrombin轉化為thrombin，cofactor Va 可加速反應 thrombin將fibrinogen轉化為fibrin fibrin clot 形成   tertiary hemostasis or clot stabilization 三級止血或凝塊穩定  thrombin的將 XIII 啟動為 XIIIa XIIIa cross-links stabilizing fibrin   Fibrinolysis 纖維蛋白溶解（凝塊溶解）  tissue-type plasminogen (tPA) 或 uPA :  plasminogen to plasmin   plasmin切割fibrin釋放fibrin degradation products(FDP) and D-dimer fibrinolysis速率取決於 tPA 濃度，該濃度由以下因素控制:  內皮分泌 tPA 的速率 肝臟清除 tPA 的速率 tPA inhibitor、PAI-1的濃度   破壞 tPA 的分泌、抑制和清除之間的平衡可導致 :  出血（fibrinolysis亢進） 血栓形成（fibrinolysis減退）     Errors in Sample Collection   基本凝血五項  📍PT 📍 aPTT📍 TT📍 FIB📍 DD   Prothrombin Time (PT) and INR Activated Partial Thromboplastin Time (aPTT) Thrombin Time (TT) Clauss Fibrinogen Assay D-dimer Test   Prothrombin Time (PT) and INR   VII（外源性途徑）、因子 II、V 和 X，以及fibrinogen（共同途徑） PT 的參考範圍因試劑和儀器而異；通常在 10 秒到 13 秒之間 INR = (patient&rsquo;s PT/ Control PT)ISI  causes of PT prolongation  underlying conditions anticoagulants acute dilutional coagulopathy  Shortened PT may suggest a hypercoagulable state, but it is not used to guide patient care in practice."><meta property="og:title" content><meta property="og:description" content><meta property="og:type" content="website"><meta property="og:url" content><meta property="og:image" content="https://og-mlkgi530p-htlin222.vercel.app/api/blog?templateTitle="><title>蜥蜴花園🦎🌱🪴🌲</title><meta name=viewport content="width=device-width,initial-scale=1"><link rel=alternate type=application/rss+xml href=https://www.physician.tw//feed.xml title><link rel="shortcut icon" type=image/png href=https://www.physician.tw//icon.png><link href=https://www.physician.tw/styles.720e2c4835986a3891d6eef3a55faa22.min.css rel=stylesheet><link href=https://www.physician.tw/styles/_light_syntax.86a48a52faebeaaf42158b72922b1c90.min.css rel=stylesheet id=theme-link><script src=https://www.physician.tw/js/darkmode.dfadb738e747a87e78c7144d7267f1bc.min.js></script>
<script src=https://www.physician.tw/js/util.6f22941e242efae60fd84e7c32e874fa.min.js></script>
<link rel=preload href=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.css as=style onload='this.onload=null,this.rel="stylesheet"' integrity=sha384-R4558gYOUz8mP9YWpZJjofhk+zx0AS11p36HnD2ZKj/6JR5z27gSSULCNHIRReVs crossorigin=anonymous><script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.js integrity=sha384-z1fJDqw8ZApjGO3/unPWUPsIymfsJmyrDVWC8Tv/a1HeOtGmkwNd/7xUS0Xcnvsx crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/contrib/auto-render.min.js integrity=sha384-+XBljXPPiv+OzfbB3cVmLHf4hdUFHlWNZN5spNQ7rmHTXpd7WvJum6fIACpNNfIR crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.16.2/dist/contrib/copy-tex.min.js integrity=sha384-ww/583aHhxWkz5DEVn6OKtNiIaLi2iBRNZXfJRiY1Ai7tnJ9UXpEsyvOITVpTl4A crossorigin=anonymous></script>
<script async src=https://unpkg.com/@floating-ui/core@0.7.3></script>
<script async src=https://unpkg.com/@floating-ui/dom@0.5.4></script>
<script async src=https://www.physician.tw/js/popover.f03552ccb84d99ca615d1cfb9abde59e.min.js></script>
<script defer src=https://www.physician.tw/js/code-title.ce4a43f09239a9efb48fee342e8ef2df.min.js></script>
<script defer src=https://www.physician.tw/js/clipboard.2913da76d3cb21c5deaa4bae7da38c9f.min.js></script>
<script defer src=https://www.physician.tw/js/callouts.7723cac461d613d118ee8bb8216b9838.min.js></script>
<script>const SEARCH_ENABLED=!1,LATEX_ENABLED=!0,PRODUCTION=!0,BASE_URL="https://www.physician.tw/",fetchData=Promise.all([fetch("https://www.physician.tw/indices/linkIndex.84393096b3899db7fcf941e10b02fd94.min.json").then(e=>e.json()).then(e=>({index:e.index,links:e.links})),fetch("https://www.physician.tw/indices/contentIndex.021556b96a3c2bac2659a9f1cb00f8e2.min.json").then(e=>e.json())]).then(([{index:e,links:t},n])=>({index:e,links:t,content:n})),render=()=>{const e=new URL(BASE_URL),t=e.pathname,n=window.location.pathname,s=t==n;addCopyButtons(),addTitleToCodeBlocks(),addCollapsibleCallouts(),initPopover("https://www.physician.tw",!0);const o=document.getElementById("footer");if(o){const e=document.getElementById("graph-container");if(!e)return requestAnimationFrame(render);e.textContent="";const t=s&&!1;drawGraph("https://www.physician.tw",t,[{"/moc":"#4388cc"}],t?{centerForce:1,depth:-1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.5,linkDistance:1,opacityScale:3,repelForce:1,scale:1.4}:{centerForce:1,depth:1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.6,linkDistance:1,opacityScale:3,repelForce:2,scale:1.2})}},init=(e=document)=>{addCopyButtons(),addTitleToCodeBlocks(),renderMathInElement(e.body,{delimiters:[{left:"$$",right:"$$",display:!0},{left:"$",right:"$",display:!1}],macros:{'’':"'"},throwOnError:!1})}</script><script type=module>
    import { attachSPARouting } from "https:\/\/www.physician.tw\/js\/router.9d4974281069e9ebb189f642ae1e3ca2.min.js"
    attachSPARouting(init, render)
  </script></head><body><div id=search-container><div id=search-space><input autocomplete=off id=search-bar name=search type=text aria-label=搜尋 placeholder="請輸入像是：hypertension 之類的來看沒有沒什麼有趣的🎳"><div id=results-container></div></div></div><script src=https://cdn.jsdelivr.net/npm/flexsearch@0.7.21/dist/flexsearch.bundle.js integrity="sha256-i3A0NZGkhsKjVMzFxv3ksk0DZh3aXqu0l49Bbh0MdjE=" crossorigin=anonymous defer></script>
<script defer src=https://www.physician.tw/js/full-text-search.e6e2e0c213187ca0c703d6e2c7a77fcd.min.js></script><div class=singlePage><header><h1 id=page-title><a href=https://www.physician.tw/>蜥蜴花園🦎🌱🪴🌲</a></h1><div class=spacer></div><div id=search-icon><p>搜尋</p><svg tabindex="0" aria-labelledby="title desc" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 19.9 19.7"><title id="title">搜尋圖示</title><desc id="desc">打開搜尋圖標</desc><g class="search-path" fill="none"><path stroke-linecap="square" d="M18.5 18.3l-5.4-5.4"/><circle cx="8" cy="8" r="7"/></g></svg></div><div class=darkmode><input class=toggle id=darkmode-toggle type=checkbox tabindex=-1>
<label id=toggle-label-light for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="dayIcon" viewBox="0 0 35 35" style="enable-background:new 0 0 35 35"><title>明亮模式</title><path d="M6 17.5C6 16.672 5.328 16 4.5 16h-3C.672 16 0 16.672.0 17.5S.672 19 1.5 19h3C5.328 19 6 18.328 6 17.5zM7.5 26c-.414.0-.789.168-1.061.439l-2 2C4.168 28.711 4 29.086 4 29.5 4 30.328 4.671 31 5.5 31c.414.0.789-.168 1.06-.44l2-2C8.832 28.289 9 27.914 9 27.5 9 26.672 8.329 26 7.5 26zm10-20C18.329 6 19 5.328 19 4.5v-3C19 .672 18.329.0 17.5.0S16 .672 16 1.5v3C16 5.328 16.671 6 17.5 6zm10 3c.414.0.789-.168 1.06-.439l2-2C30.832 6.289 31 5.914 31 5.5 31 4.672 30.329 4 29.5 4c-.414.0-.789.168-1.061.44l-2 2C26.168 6.711 26 7.086 26 7.5 26 8.328 26.671 9 27.5 9zM6.439 8.561C6.711 8.832 7.086 9 7.5 9 8.328 9 9 8.328 9 7.5c0-.414-.168-.789-.439-1.061l-2-2C6.289 4.168 5.914 4 5.5 4 4.672 4 4 4.672 4 5.5c0 .414.168.789.439 1.06l2 2.001zM33.5 16h-3c-.828.0-1.5.672-1.5 1.5s.672 1.5 1.5 1.5h3c.828.0 1.5-.672 1.5-1.5S34.328 16 33.5 16zM28.561 26.439C28.289 26.168 27.914 26 27.5 26c-.828.0-1.5.672-1.5 1.5.0.414.168.789.439 1.06l2 2C28.711 30.832 29.086 31 29.5 31c.828.0 1.5-.672 1.5-1.5.0-.414-.168-.789-.439-1.061l-2-2zM17.5 29c-.829.0-1.5.672-1.5 1.5v3c0 .828.671 1.5 1.5 1.5s1.5-.672 1.5-1.5v-3C19 29.672 18.329 29 17.5 29zm0-22C11.71 7 7 11.71 7 17.5S11.71 28 17.5 28 28 23.29 28 17.5 23.29 7 17.5 7zm0 18c-4.136.0-7.5-3.364-7.5-7.5s3.364-7.5 7.5-7.5 7.5 3.364 7.5 7.5S21.636 25 17.5 25z"/></svg></label><label id=toggle-label-dark for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="nightIcon" viewBox="0 0 100 100" style="enable-background='new 0 0 100 100'"><title>黑暗模式</title><path d="M96.76 66.458c-.853-.852-2.15-1.064-3.23-.534-6.063 2.991-12.858 4.571-19.655 4.571C62.022 70.495 50.88 65.88 42.5 57.5 29.043 44.043 25.658 23.536 34.076 6.47c.532-1.08.318-2.379-.534-3.23-.851-.852-2.15-1.064-3.23-.534-4.918 2.427-9.375 5.619-13.246 9.491-9.447 9.447-14.65 22.008-14.65 35.369.0 13.36 5.203 25.921 14.65 35.368s22.008 14.65 35.368 14.65c13.361.0 25.921-5.203 35.369-14.65 3.872-3.871 7.064-8.328 9.491-13.246C97.826 68.608 97.611 67.309 96.76 66.458z"/></svg></label></div></header><article><p class=meta>最後更新於
Aug 28, 2023
<a href=https://github.com/htlin222/garden/tree/hugo/content/slides/coagulation_test.md rel=noopener>🪚 編輯原始文件</a></p><ul class=tags></ul><aside class=mainTOC><details><summary>📒目錄</summary><nav id=TableOfContents><ol><li><ol><li><a href=#林協霆>林協霆</a></li></ol></li></ol><ol><li><ol><li><a href=#primary-hemostasis--初級止血>primary hemostasis 初級止血</a></li><li><a href=#secondary-hemostasis-二級止血>secondary hemostasis 二級止血</a></li></ol></li><li><a href=#primary-hemostasis--初級止血-1>primary hemostasis 初級止血</a><ol><li><a href=#secretion-of-storage-granule-content>secretion of storage granule content</a></li><li><a href=#during-platelet-activation-血小板活化>during platelet activation 血小板活化</a></li><li><a href=#platelet-aggregation--血小板聚集>platelet aggregation 血小板聚集</a></li></ol></li><li><a href=#secondary-hemostasis-二級止血-1>secondary hemostasis 二級止血</a></li><li><a href=#coagulation-factor---i>Coagulation Factor - I</a></li><li><a href=#coagulation-factor---ii>Coagulation Factor - II</a></li><li><a href=#extrinsic-pathway>Extrinsic pathway</a></li><li><a href=#intrinsic-pathway>Intrinsic pathway</a></li><li><a href=#然後兩條路徑匯聚到common-pathwya共同路徑>然後兩條路徑匯聚到Common Pathwya共同路徑</a></li><li><a href=#tertiary-hemostasis-or-clot-stabilization-三級止血或凝塊穩定>tertiary hemostasis or clot stabilization 三級止血或凝塊穩定</a></li><li><a href=#fibrinolysis-纖維蛋白溶解凝塊溶解>Fibrinolysis 纖維蛋白溶解（凝塊溶解）</a><ol><li><a href=#errors-in-sample-collection>Errors in Sample Collection</a></li></ol></li></ol><ol><li><ol><li><a href=#pt--aptt-tt-fib-dd>📍PT 📍 aPTT📍 TT📍 FIB📍 DD</a></li></ol></li><li><a href=#prothrombin-time-pt-and-inr>Prothrombin Time (PT) and INR</a></li><li><a href=#causes-of-pt-prolongation>causes of PT prolongation</a><ol><li></li><li><a href=#1-pt-prolongtaion--underlying-conditions>1. PT prolongtaion : underlying conditions</a></li><li><a href=#2-pt-prolongtaion--anticoagulants>2. PT prolongtaion : anticoagulants</a></li></ol></li><li><a href=#limitations-of-pt>limitations of PT</a></li><li><a href=#activated-partial-thromboplastin-time-aptt>Activated Partial Thromboplastin Time (aPTT)</a></li><li><a href=#causes-of-aptt-prolongation>causes of aPTT prolongation</a><ol><li><a href=#anticoagulants-cause-aptt-prolognation>anticoagulants cause aPTT prolognation</a></li></ol></li><li><a href=#thrombin-time-tt>Thrombin Time (TT)</a></li><li><a href=#shourt-summary>Shourt Summary:</a><ol><li><a href=#screening-test-abnormalities-in-inherited-and-acquired-coagulopathies>Screening Test Abnormalities in Inherited and Acquired Coagulopathies</a></li></ol></li><li><a href=#fibrinogen-assay>Fibrinogen Assay</a><ol><li><a href=#fibrinogen-100-mgdl--cryoprecipitate>fibrinogen &lt;100 mg/dL : Cryoprecipitate</a></li></ol></li><li><a href=#d-dimer-test>D-dimer Test</a></li><li><a href=#cutoff-typically--500-mcgl-to-define-negative-d-dimer-assay>cutoff (typically &lt; 500 mcg/L) to define negative D-dimer assay</a></li><li><a href=#other-conditions-of-elevtaed-d-dimer>Other conditions of elevtaed D-Dimer</a></li><li><a href=#mixing-study>Mixing study:</a></li><li><a href=#coagulation-factor-levels>Coagulation factor levels:</a></li><li><a href=#dic-screen>DIC screen:</a></li></ol><ol><li><a href=#plt->Plt: ⬇️</a></li><li><a href=#pt-->PT: 🆗</a></li><li><a href=#aptt->aPTT: 🆗</a></li><li><a href=#tt->TT: 🆗</a></li><li><a href=#fibrinogen->Fibrinogen: 🆗</a></li></ol><ol><li><a href=#thrombocytopenia>Thrombocytopenia</a></li></ol><ol><li><a href=#plt--1>Plt: 🆗</a></li><li><a href=#pt->PT: ⌛⌛⌛⌛⌛</a></li><li><a href=#aptt--1>aPTT: 🆗</a></li><li><a href=#tt--1>TT: 🆗</a></li><li><a href=#fibrinogen--1>Fibrinogen: 🆗</a></li></ol><ol><li><a href=#plt--2>Plt: 🆗</a></li><li><a href=#pt---1>PT: 🆗</a></li><li><a href=#aptt--2>aPTT: ⌛⌛⌛⌛⌛</a></li><li><a href=#tt--2>TT: 🆗</a></li><li><a href=#fibrinogen--2>Fibrinogen: 🆗</a></li></ol><ol><li><a href=#plt--3>Plt: 🆗</a></li><li><a href=#pt--1>PT: ⌛⌛⌛⌛⌛</a></li><li><a href=#aptt--3>aPTT: ⌛⌛⌛⌛⌛</a></li><li><a href=#tt--3>TT: 🆗</a></li><li><a href=#fibrinogen--3>Fibrinogen: 🆗</a></li></ol><ol><li><a href=#plt--4>Plt: 🆗</a></li><li><a href=#pt--2>PT: 🆗/⌛⌛⌛</a></li><li><a href=#aptt--4>aPTT: 🆗/⌛⌛⌛</a></li><li><a href=#tt--4>TT: ⌛⌛⌛⌛⌛</a></li><li><a href=#fibrinogen--4>Fibrinogen: ⬇️</a></li></ol><ol><li><a href=#plt--5>Plt: 🆗</a></li><li><a href=#pt---2>PT: ⌛⌛⌛⌛⌛⌛⌛⌛⌛⌛</a></li><li><a href=#aptt--5>aPTT: ⌛⌛⌛⌛⌛⌛⌛⌛⌛⌛</a></li><li><a href=#tt--5>TT: ⌛⌛⌛⌛⌛⌛⌛⌛⌛⌛</a></li><li><a href=#fibrinogen--5>Fibrinogen: ❌</a></li></ol><ol><li><a href=#plt--6>Plt: ⬇️</a></li><li><a href=#pt---3>PT: 🆗/⌛⌛⌛</a></li><li><a href=#aptt--6>aPTT: 🆗/⌛⌛⌛</a></li><li><a href=#tt--6>TT: 🆗/⌛⌛⌛</a></li><li><a href=#fibrinogen--6>Fibrinogen: 🆗/⬇️</a></li></ol><ol><li><a href=#dic>DIC</a></li></ol><ol><li><a href=#plt--7>Plt: 🆗</a></li><li><a href=#pt---4>PT: 🆗</a></li><li><a href=#aptt--7>aPTT: 🆗</a></li><li><a href=#tt--7>TT: 🆗</a></li><li><a href=#fibrinogen--7>Fibrinogen: 🆗</a></li></ol><ol><li><a href=#andexanet-alfa-factor-xa-decoy-receptor>Andexanet alfa (factor Xa decoy receptor)</a></li></ol></nav></details></aside><style scoped>h1{font-size:150px;font-weight:900}</style><a href=#coagultaion-testing><h1 id=coagultaion-testing><span class=hanchor arialabel=Anchor># </span>Coagultaion Testing</h1></a><hr><a href=#林協霆><h3 id=林協霆><span class=hanchor arialabel=Anchor># </span>林協霆</h3></a><p>2023.05.31</p><hr><a href=#overview-of-hemostasis><h1 id=overview-of-hemostasis><span class=hanchor arialabel=Anchor># </span>Overview of Hemostasis</h1></a><a href=#primary-hemostasis--初級止血><h3 id=primary-hemostasis--初級止血><span class=hanchor arialabel=Anchor># </span>primary hemostasis 初級止血</h3></a><a href=#secondary-hemostasis-二級止血><h3 id=secondary-hemostasis-二級止血><span class=hanchor arialabel=Anchor># </span>secondary hemostasis 二級止血</h3></a><hr><a href=#primary-hemostasis--初級止血-1><h2 id=primary-hemostasis--初級止血-1><span class=hanchor arialabel=Anchor># </span>primary hemostasis 初級止血</h2></a><ul><li>血小板的正常功能 : 👮監測血管內皮的完整性並在血管損傷部位形成栓塞以阻止和防止血液滲漏到血管外</li><li>沒有血管損傷 : 前列環素（prostaglandin）和內皮細胞分泌的一氧化氮的抑制🔐</li><li>血管損傷和內皮損傷<ul><li>交感神經系統被啟動並引起血管收縮</li><li>collagen, fibronectin, and laminin : exposed to circulating blood</li><li>👷血小板附在暴露的內皮下基質蛋白上，開始止血栓形成過程</li></ul></li></ul><hr><a href=#secretion-of-storage-granule-content><h3 id=secretion-of-storage-granule-content><span class=hanchor arialabel=Anchor># </span>secretion of storage granule content</h3></a><ul><li>血小板顆粒 : 含有數千種蛋白質，啟動後釋放</li><li><code>3 major secretory granules</code><ul><li>alpha-granules<ul><li>凝血因子（I、II、V 和 XI）、</li><li>fibrinolysis system components</li><li>coagulation inhibitors</li><li>complement components (C1 inhibitor, C3, and C4)</li></ul></li><li>delta-granules<ul><li>ADP</li></ul></li><li>lysosomes</li></ul></li></ul><hr><a href=#during-platelet-activation-血小板活化><h3 id=during-platelet-activation-血小板活化><span class=hanchor arialabel=Anchor># </span>during platelet activation 血小板活化</h3></a><ul><li>（ADP、thromboxane A2）啟動信號通路，將 GPIIb/IIIa 轉化為 divalent fibrinogen</li><li>fibrinogen 👉 聚集/凝聚</li></ul><a href=#platelet-aggregation--血小板聚集><h3 id=platelet-aggregation--血小板聚集><span class=hanchor arialabel=Anchor># </span>platelet aggregation 血小板聚集</h3></a><ul><li>GPIIb/IIIa<ul><li>募集額外的血小板</li></ul></li><li>transmembrane ADP receptors P2Y1 and P2Y12<ul><li>血小板形態學變化</li><li>血小板聚集</li></ul></li></ul><hr><a href=#secondary-hemostasis-二級止血-1><h2 id=secondary-hemostasis-二級止血-1><span class=hanchor arialabel=Anchor># </span>secondary hemostasis 二級止血</h2></a><ul><li>沒流血時：<ul><li>inactive precursor enzymes (zymogens)</li><li>在血漿中循環</li></ul></li><li>流血時：<ul><li>導致fibrin polymerization和血小板活化，</li><li>形成clot</li></ul></li><li>2 個途徑 :<ul><li>extrinsic</li><li>intrinsic</li></ul></li></ul><hr><p><img src=https://i.imgur.com/A4GWEtH.png width=auto alt=" h:650"></p><hr><a href=#coagulation-factor---i><h2 id=coagulation-factor---i><span class=hanchor arialabel=Anchor># </span>Coagulation Factor - I</h2></a><ol><li>I - fibrinogen</li><li>II - prothrombin</li></ol><hr><ol start=3><li>III - tissue thromboplastin (tissue factor)</li></ol><hr><ol start=4><li>IV - ionized calcium ( Ca++ )</li><li>V - labile factor or proaccelerin</li></ol><ul><li>PL : platelet membrane phospholipid</li></ul><hr><ol start=7><li>VII - stable factor or proconvertin</li></ol><hr><a href=#coagulation-factor---ii><h2 id=coagulation-factor---ii><span class=hanchor arialabel=Anchor># </span>Coagulation Factor - II</h2></a><ol start=8><li>VIII - antihemophilic factor</li><li>IX - plasma thromboplastin component, Christmas factor</li><li><code>X - Stuart-Prower factor</code></li><li>XI - plasma thromboplastin antecedent</li><li>XII - Hageman factor</li></ol><hr><ol start=13><li>XIII - fibrin-stabilizing factor</li></ol><hr><a href=#extrinsic-pathway><h2 id=extrinsic-pathway><span class=hanchor arialabel=Anchor># </span>Extrinsic pathway</h2></a><ul><li>血管損傷或單核細胞啟動導致 VII（VIIa）啟動</li><li>啟動 IX (intrinsic）和 X（common）</li></ul><a href=#intrinsic-pathway><h2 id=intrinsic-pathway><span class=hanchor arialabel=Anchor># </span>Intrinsic pathway</h2></a><ul><li>由 XII 轉化為 XIIa 開始</li><li>XI 和 IX 逐步轉化為其活性形式</li><li>VIIIa （由thrombin啟動）<ul><li>在活化的血小板表面作為 IXa 的Cofactor</li><li>促進 X to Xa</li></ul></li></ul><hr><a href=#然後兩條路徑匯聚到common-pathwya共同路徑><h2 id=然後兩條路徑匯聚到common-pathwya共同路徑><span class=hanchor arialabel=Anchor># </span>然後兩條路徑匯聚到Common Pathwya共同路徑</h2></a><ul><li>X啟動為Xa</li><li>Xa 將prothrombin轉化為thrombin，cofactor Va 可加速反應</li><li>thrombin將fibrinogen轉化為fibrin</li><li>fibrin clot 形成</li></ul><hr><a href=#tertiary-hemostasis-or-clot-stabilization-三級止血或凝塊穩定><h2 id=tertiary-hemostasis-or-clot-stabilization-三級止血或凝塊穩定><span class=hanchor arialabel=Anchor># </span>tertiary hemostasis or clot stabilization 三級止血或凝塊穩定</h2></a><ul><li>thrombin的將 XIII 啟動為 XIIIa</li><li>XIIIa <code>cross-links</code> stabilizing fibrin</li></ul><hr><a href=#fibrinolysis-纖維蛋白溶解凝塊溶解><h2 id=fibrinolysis-纖維蛋白溶解凝塊溶解><span class=hanchor arialabel=Anchor># </span>Fibrinolysis 纖維蛋白溶解（凝塊溶解）</h2></a><ul><li>tissue-type plasminogen (tPA) 或 uPA :<ul><li>plasminogen to plasmin</li></ul></li><li>plasmin切割fibrin釋放fibrin degradation products(FDP) and D-dimer</li><li>fibrinolysis速率取決於 tPA 濃度，該濃度由以下因素控制:<ul><li>內皮分泌 tPA 的速率</li><li>肝臟清除 tPA 的速率</li><li>tPA inhibitor、PAI-1的濃度</li></ul></li><li>破壞 tPA 的分泌、抑制和清除之間的平衡可導致 :<ul><li>出血（fibrinolysis亢進）</li><li>血栓形成（fibrinolysis減退）</li></ul></li></ul><hr><a href=#errors-in-sample-collection><h3 id=errors-in-sample-collection><span class=hanchor arialabel=Anchor># </span>Errors in Sample Collection</h3></a><p><img src=https://i.imgur.com/VAACBhR.png width=auto alt=" h:550"></p><hr><a href=#基本凝血五項><h1 id=基本凝血五項><span class=hanchor arialabel=Anchor># </span>基本凝血五項</h1></a><hr><a href=#pt--aptt-tt-fib-dd><h3 id=pt--aptt-tt-fib-dd><span class=hanchor arialabel=Anchor># </span>📍PT 📍 aPTT📍 TT📍 FIB📍 DD</h3></a><hr><ol><li>Prothrombin Time (PT) and INR</li><li>Activated Partial Thromboplastin Time (aPTT)</li><li>Thrombin Time (TT)</li><li>Clauss Fibrinogen Assay</li><li>D-dimer Test</li></ol><hr><a href=#prothrombin-time-pt-and-inr><h2 id=prothrombin-time-pt-and-inr><span class=hanchor arialabel=Anchor># </span>Prothrombin Time (PT) and INR</h2></a><hr><ul><li>VII（外源性途徑）、因子 II、V 和 X，以及fibrinogen（共同途徑）</li><li>PT 的參考範圍因試劑和儀器而異；通常在 10 秒到 13 秒之間</li><li>INR = (patient&rsquo;s PT/ Control PT)<sup>ISI</sup></li></ul><a href=#causes-of-pt-prolongation><h2 id=causes-of-pt-prolongation><span class=hanchor arialabel=Anchor># </span>causes of PT prolongation</h2></a><ol><li>underlying conditions</li><li>anticoagulants</li><li>acute dilutional coagulopathy</li></ol><a href=#shortened-pt-may-suggest-a-hypercoagulable-state-but-it-is-not-used-to-guide-patient-care-in-practice><h6 id=shortened-pt-may-suggest-a-hypercoagulable-state-but-it-is-not-used-to-guide-patient-care-in-practice><span class=hanchor arialabel=Anchor># </span>Shortened PT may suggest a hypercoagulable state, but it is not used to guide patient care in practice.</h6></a><hr><a href=#1-pt-prolongtaion--underlying-conditions><h3 id=1-pt-prolongtaion--underlying-conditions><span class=hanchor arialabel=Anchor># </span>1. PT prolongtaion : underlying conditions</h3></a><ul><li>factor VII (extrinsic pathway)</li><li>factors V, VII, and/or X, prothrombin, and/or fibrinogen (common pathway)</li><li><code>vitamin K deficiency</code></li><li>liver disease</li><li>afibrinogenemia, hypofibrinogenemia, or dysfibrinogenemia
disseminated intravascular coagulation</li><li>elevated fibrin degradation products</li><li>some lupus anticoagulant (uncommon)/antiphospholipid antibodies</li></ul><hr><a href=#2-pt-prolongtaion--anticoagulants><h3 id=2-pt-prolongtaion--anticoagulants><span class=hanchor arialabel=Anchor># </span>2. PT prolongtaion : anticoagulants</h3></a><ul><li>vitamin K antagonists including <code>warfarin</code></li><li>factor Xa inhibitors including <code>rivaroxaban</code> and to a lesser extent, apixaban</li><li><code>unfractionated heparin</code> (generally at high doses; PT/INR not typically affected by low-molecular-weight heparin)</li><li>parenteral or oral direct thrombin inhibitors such as bivalirudin or dabigatran</li></ul><hr><a href=#limitations-of-pt><h2 id=limitations-of-pt><span class=hanchor arialabel=Anchor># </span>limitations of PT</h2></a><ul><li>inability to detect most <code>fibrinogen disorders</code></li><li>there are variations among PT assay reagents with different sensitivities to factor deficiencies, thus<ul><li>normal PT <code>does not rule out factor deficiencies</code></li><li>prolonged PT <code>does not necessarily reflect bleeding risk</code></li></ul></li></ul><hr><a href=#activated-partial-thromboplastin-time-aptt><h2 id=activated-partial-thromboplastin-time-aptt><span class=hanchor arialabel=Anchor># </span>Activated Partial Thromboplastin Time (aPTT)</h2></a><ul><li>factors XII, XI, IX, VIII (intrinsic pathway)</li><li>factors II, V, and X, and fibrinogen (common pathway)</li></ul><hr><ul><li>screening : bleeding disorders due to deficiencies of, or inhibitors to coagulation factors</li><li>monitoring : unfractionated heparin therapy</li><li>assessment : disseminated intravascular coagulation</li><li>monitoring : liver disease status</li><li>screening : lupus anticoagulant</li></ul><hr><a href=#causes-of-aptt-prolongation><h2 id=causes-of-aptt-prolongation><span class=hanchor arialabel=Anchor># </span>causes of aPTT prolongation</h2></a><ul><li><code>factor XII deficiency</code> : most common</li><li>acquired or inherited deficiencies or inhibition<ul><li>factors XI, IX (<code>hemophilia B</code>),</li><li>factors VIII (including <code>hemophilia A</code>), X, II, and fibrinogen (though aPTT does not detect most fibrinogen disorders)</li></ul></li><li><code>vitamin K deficiency</code></li><li>presence of <code>lupus anticoagulant</code></li><li>severe <code>von Willebrand disease</code></li><li>disseminated intravascular coagulation (DIC)</li><li>liver disease</li></ul><hr><a href=#anticoagulants-cause-aptt-prolognation><h3 id=anticoagulants-cause-aptt-prolognation><span class=hanchor arialabel=Anchor># </span>anticoagulants cause aPTT prolognation</h3></a><ul><li>high doses of vitamin K antagonists, <strong>although prothrombin time</strong> is more sensitive for vitamin K antagonist</li><li>heparin (particularly unfractionated heparin)</li><li>bivalirudin or dabigatran</li><li>factor Xa inhibitors such as apixaban and rivaroxaban</li></ul><hr><a href=#thrombin-time-tt><h2 id=thrombin-time-tt><span class=hanchor arialabel=Anchor># </span>Thrombin Time (TT)</h2></a><ul><li>detection of <code>hypofibrinogenemia and dysfibrinogenemia</code></li><li>detection of <code>thrombin inhibitors</code></li><li>other testing usually provide sufficient information without the use of TT in patients requiring investigation of inherited disorders of secondary hemostasis</li></ul><hr><a href=#shourt-summary><h2 id=shourt-summary><span class=hanchor arialabel=Anchor># </span>Shourt Summary:</h2></a><hr><a href=#screening-test-abnormalities-in-inherited-and-acquired-coagulopathies><h3 id=screening-test-abnormalities-in-inherited-and-acquired-coagulopathies><span class=hanchor arialabel=Anchor># </span>Screening Test Abnormalities in Inherited and Acquired Coagulopathies</h3></a><p><img src=https://i.imgur.com/Pl2E669.png width=auto alt=h:200></p><hr><a href=#fibrinogen-assay><h2 id=fibrinogen-assay><span class=hanchor arialabel=Anchor># </span>Fibrinogen Assay</h2></a><p>normal fibrinogen concentration ranges from 200 mg/dL (2 g/L) to 400 mg/dL (4 g/L)</p><hr><ul><li>afibrinogenemia, hypofibrinogenemia, and dysfibrinogenemia</li><li>liver disease</li><li>disseminated intravascular coagulation (DIC)</li><li>primary fibrinolysis</li></ul><a href=#fibrinogen-100-mgdl--cryoprecipitate><h3 id=fibrinogen-100-mgdl--cryoprecipitate><span class=hanchor arialabel=Anchor># </span>fibrinogen &lt;100 mg/dL : Cryoprecipitate</h3></a><ul><li>1 unit of cryo per 5kg patient weight will increase fibrinogen by about 100 mg/dL</li></ul><hr><a href=#d-dimer-test><h2 id=d-dimer-test><span class=hanchor arialabel=Anchor># </span>D-dimer Test</h2></a><ul><li>exclusion of venous thromboembolism (VTE) in patients with low clinical probability by clinical prediction scores</li><li>prediction of risk of recurrent VTE, thus aiding in decision making regarding duration of anticoagulation therapy in patients with VTE</li><li>diagnosis and management of <strong>disseminated intravascular coagulation</strong></li><li>exclusion of <strong>acute aortic dissection</strong></li><li>monitoring for thrombotic complications in patients with severe infections and sepsis</li></ul><hr><p><img src=https://i.imgur.com/4XKXKgG.png width=auto alt=" h:600"></p><blockquote><p>Freund Y, Cohen-Aubart F, Bloom B. Acute Pulmonary Embolism: A Review. JAMA. 2022;328(13):1336-1345. doi:10.1001/jama.2022.16815</p></blockquote><hr><a href=#cutoff-typically--500-mcgl-to-define-negative-d-dimer-assay><h2 id=cutoff-typically--500-mcgl-to-define-negative-d-dimer-assay><span class=hanchor arialabel=Anchor># </span>cutoff (typically &lt; 500 mcg/L) to define negative D-dimer assay</h2></a><ul><li>higher threshold (&lt; 1,000 mcg/L) in patients with low clinical pretest probability</li><li>cutoff of &lt; 500 mcg/L may be used in patients with moderate pretest probability</li></ul><hr><a href=#other-conditions-of-elevtaed-d-dimer><h2 id=other-conditions-of-elevtaed-d-dimer><span class=hanchor arialabel=Anchor># </span>Other conditions of elevtaed D-Dimer</h2></a><ul><li>being an inpatient</li><li>advanced age</li><li>cancer</li><li>disseminated intravascular coagulation (DIC)</li><li>infection</li><li>inflammatory conditions</li><li>recent surgery or trauma</li><li>liver disease, renal disease</li><li>atrial fibrillation</li><li>stroke</li><li>thrombolytic therapy</li></ul><hr><a href=#mixing-study><h2 id=mixing-study><span class=hanchor arialabel=Anchor># </span>Mixing study:</h2></a><ul><li>useful if ⬆️ PT or PTT</li><li>mix Pt’s plasma 1:1 with normal plasma</li><li>and retest<ul><li>PT/PTT normalizes<ul><li>👉 factor deficiency</li></ul></li><li>PT/PTT remains elevated<ul><li>👉 factor inhibitor</li></ul></li></ul></li></ul><hr><a href=#coagulation-factor-levels><h2 id=coagulation-factor-levels><span class=hanchor arialabel=Anchor># </span>Coagulation factor levels:</h2></a><ul><li>useful if mixing study suggests factor deficiency</li><li>DIC → all factors consumed
∴ ↓ factors V and VIII</li><li>Liver disease
→ ↓ all factors except VIII
∴ ↓ factor V, normal factor VIII</li><li>Vitamin K deficiency
→ ↓ factors II, VII, IX, X (and protein C, S);
∴ normal V and VIII</li></ul><hr><p>VIII: by vascular, glomerular, and tubular endothelium, and the sinusoidal cells of the liver</p><hr><a href=#dic-screen><h2 id=dic-screen><span class=hanchor arialabel=Anchor># </span>DIC screen:</h2></a><ul><li>↓ fibrinogen
(consumed)</li><li>fibrin degradation products
(FDPs, ⊕ from intense fibrinolysis),</li><li>↑ D-dimer
(more specific FDP test that detects degradation of X-linked fibrin)</li></ul><hr><a href=#question-1><h1 id=question-1><span class=hanchor arialabel=Anchor># </span>Question 1:</h1></a><hr><br><a href=#plt-><h2 id=plt-><span class=hanchor arialabel=Anchor># </span>Plt: ⬇️</h2></a><a href=#pt--><h2 id=pt--><span class=hanchor arialabel=Anchor># </span>PT: 🆗</h2></a><a href=#aptt-><h2 id=aptt-><span class=hanchor arialabel=Anchor># </span>aPTT: 🆗</h2></a><a href=#tt-><h2 id=tt-><span class=hanchor arialabel=Anchor># </span>TT: 🆗</h2></a><a href=#fibrinogen-><h2 id=fibrinogen-><span class=hanchor arialabel=Anchor># </span>Fibrinogen: 🆗</h2></a><hr><a href=#answer><h1 id=answer><span class=hanchor arialabel=Anchor># </span>Answer</h1></a><hr><a href=#thrombocytopenia><h2 id=thrombocytopenia><span class=hanchor arialabel=Anchor># </span>Thrombocytopenia</h2></a><hr><a href=#question-2><h1 id=question-2><span class=hanchor arialabel=Anchor># </span>Question 2:</h1></a><hr><br><a href=#plt--1><h2 id=plt--1><span class=hanchor arialabel=Anchor># </span>Plt: 🆗</h2></a><a href=#pt-><h2 id=pt-><span class=hanchor arialabel=Anchor># </span>PT: ⌛⌛⌛⌛⌛</h2></a><a href=#aptt--1><h2 id=aptt--1><span class=hanchor arialabel=Anchor># </span>aPTT: 🆗</h2></a><a href=#tt--1><h2 id=tt--1><span class=hanchor arialabel=Anchor># </span>TT: 🆗</h2></a><a href=#fibrinogen--1><h2 id=fibrinogen--1><span class=hanchor arialabel=Anchor># </span>Fibrinogen: 🆗</h2></a><hr><a href=#answer-1><h1 id=answer-1><span class=hanchor arialabel=Anchor># </span>Answer</h1></a><hr><ul><li>Factor VII deficiency or inhibitor</li><li>early vitamin K deficiency</li></ul><hr><a href=#question-3><h1 id=question-3><span class=hanchor arialabel=Anchor># </span>Question 3:</h1></a><hr><br><a href=#plt--2><h2 id=plt--2><span class=hanchor arialabel=Anchor># </span>Plt: 🆗</h2></a><a href=#pt---1><h2 id=pt---1><span class=hanchor arialabel=Anchor># </span>PT: 🆗</h2></a><a href=#aptt--2><h2 id=aptt--2><span class=hanchor arialabel=Anchor># </span>aPTT: ⌛⌛⌛⌛⌛</h2></a><a href=#tt--2><h2 id=tt--2><span class=hanchor arialabel=Anchor># </span>TT: 🆗</h2></a><a href=#fibrinogen--2><h2 id=fibrinogen--2><span class=hanchor arialabel=Anchor># </span>Fibrinogen: 🆗</h2></a><hr><a href=#answer-2><h1 id=answer-2><span class=hanchor arialabel=Anchor># </span>Answer</h1></a><hr><ul><li>Factor VIII, IX, or XI deficiency or inhibitor</li><li>Factor XII, prekallikrein, high-molecular-weight kininogen deficiency</li><li>vWD</li><li>Lupus Anticoagulant</li></ul><hr><a href=#question-4><h1 id=question-4><span class=hanchor arialabel=Anchor># </span>Question 4:</h1></a><hr><br><a href=#plt--3><h2 id=plt--3><span class=hanchor arialabel=Anchor># </span>Plt: 🆗</h2></a><a href=#pt--1><h2 id=pt--1><span class=hanchor arialabel=Anchor># </span>PT: ⌛⌛⌛⌛⌛</h2></a><a href=#aptt--3><h2 id=aptt--3><span class=hanchor arialabel=Anchor># </span>aPTT: ⌛⌛⌛⌛⌛</h2></a><a href=#tt--3><h2 id=tt--3><span class=hanchor arialabel=Anchor># </span>TT: 🆗</h2></a><a href=#fibrinogen--3><h2 id=fibrinogen--3><span class=hanchor arialabel=Anchor># </span>Fibrinogen: 🆗</h2></a><hr><a href=#answer-3><h1 id=answer-3><span class=hanchor arialabel=Anchor># </span>Answer</h1></a><hr><ul><li>Prothrombin, factor V, or factor X deficiency or inhibitor</li><li>Deficiency or inhibitor against factors in both intrinsic and extrinsic pathway,<ul><li>for example,<ul><li>liver disease</li><li>DIC,</li><li>vitamin K deficiency</li></ul></li></ul></li><li>Factor V Short</li></ul><hr><a href=#question-5><h1 id=question-5><span class=hanchor arialabel=Anchor># </span>Question 5:</h1></a><hr><br><a href=#plt--4><h2 id=plt--4><span class=hanchor arialabel=Anchor># </span>Plt: 🆗</h2></a><a href=#pt--2><h2 id=pt--2><span class=hanchor arialabel=Anchor># </span>PT: 🆗/⌛⌛⌛</h2></a><a href=#aptt--4><h2 id=aptt--4><span class=hanchor arialabel=Anchor># </span>aPTT: 🆗/⌛⌛⌛</h2></a><a href=#tt--4><h2 id=tt--4><span class=hanchor arialabel=Anchor># </span>TT: ⌛⌛⌛⌛⌛</h2></a><a href=#fibrinogen--4><h2 id=fibrinogen--4><span class=hanchor arialabel=Anchor># </span>Fibrinogen: ⬇️</h2></a><hr><a href=#answer-4><h1 id=answer-4><span class=hanchor arialabel=Anchor># </span>Answer</h1></a><hr><ul><li>Hypofibrinogenemia</li><li>Dysfibrinogenemia</li></ul><hr><a href=#question-6><h1 id=question-6><span class=hanchor arialabel=Anchor># </span>Question 6:</h1></a><hr><br><a href=#plt--5><h2 id=plt--5><span class=hanchor arialabel=Anchor># </span>Plt: 🆗</h2></a><a href=#pt---2><h2 id=pt---2><span class=hanchor arialabel=Anchor># </span>PT: ⌛⌛⌛⌛⌛⌛⌛⌛⌛⌛</h2></a><a href=#aptt--5><h2 id=aptt--5><span class=hanchor arialabel=Anchor># </span>aPTT: ⌛⌛⌛⌛⌛⌛⌛⌛⌛⌛</h2></a><a href=#tt--5><h2 id=tt--5><span class=hanchor arialabel=Anchor># </span>TT: ⌛⌛⌛⌛⌛⌛⌛⌛⌛⌛</h2></a><a href=#fibrinogen--5><h2 id=fibrinogen--5><span class=hanchor arialabel=Anchor># </span>Fibrinogen: ❌</h2></a><hr><a href=#answer-5><h1 id=answer-5><span class=hanchor arialabel=Anchor># </span>Answer</h1></a><hr><ul><li>Afibrinogenemia</li></ul><hr><a href=#question-7><h1 id=question-7><span class=hanchor arialabel=Anchor># </span>Question 7:</h1></a><hr><br><a href=#plt--6><h2 id=plt--6><span class=hanchor arialabel=Anchor># </span>Plt: ⬇️</h2></a><a href=#pt---3><h2 id=pt---3><span class=hanchor arialabel=Anchor># </span>PT: 🆗/⌛⌛⌛</h2></a><a href=#aptt--6><h2 id=aptt--6><span class=hanchor arialabel=Anchor># </span>aPTT: 🆗/⌛⌛⌛</h2></a><a href=#tt--6><h2 id=tt--6><span class=hanchor arialabel=Anchor># </span>TT: 🆗/⌛⌛⌛</h2></a><a href=#fibrinogen--6><h2 id=fibrinogen--6><span class=hanchor arialabel=Anchor># </span>Fibrinogen: 🆗/⬇️</h2></a><hr><a href=#answer-6><h1 id=answer-6><span class=hanchor arialabel=Anchor># </span>Answer</h1></a><hr><a href=#dic><h2 id=dic><span class=hanchor arialabel=Anchor># </span>DIC</h2></a><hr><a href=#question-8><h1 id=question-8><span class=hanchor arialabel=Anchor># </span>Question 8:</h1></a><hr><br><a href=#plt--7><h2 id=plt--7><span class=hanchor arialabel=Anchor># </span>Plt: 🆗</h2></a><a href=#pt---4><h2 id=pt---4><span class=hanchor arialabel=Anchor># </span>PT: 🆗</h2></a><a href=#aptt--7><h2 id=aptt--7><span class=hanchor arialabel=Anchor># </span>aPTT: 🆗</h2></a><a href=#tt--7><h2 id=tt--7><span class=hanchor arialabel=Anchor># </span>TT: 🆗</h2></a><a href=#fibrinogen--7><h2 id=fibrinogen--7><span class=hanchor arialabel=Anchor># </span>Fibrinogen: 🆗</h2></a><hr><a href=#answer-7><h1 id=answer-7><span class=hanchor arialabel=Anchor># </span>Answer</h1></a><hr><ul><li>Factor <code>XIII deficiency</code> or inhibitor</li><li>Fibrinolytic defects</li><li><code>vWD</code> (only affecting collagen binding function, though aPTT is often elevated)</li><li>Disorder of <code>blood vessel wall</code></li><li>Combination of mild deficiency of coagulation factors, VWF, and undetected IPFD</li><li><code>Platelet function defects</code> e.g. CKD</li></ul><hr><a href=#clotting-cascade-and-anticoagulants><h1 id=clotting-cascade-and-anticoagulants><span class=hanchor arialabel=Anchor># </span>Clotting cascade and anticoagulants</h1></a><hr><p><img src=https://i.imgur.com/RG3EW7j.png width=auto alt=h:550></p><hr><p>Properties and Antidotes for Anticoagulants & Fibrinolytics</p><table><thead><tr><th>Anticoag.</th><th>t1/2</th><th>Labs</th><th>Rx for O/D w/ Serious Bleeding (+ d/c anticoag)</th></tr></thead><tbody><tr><td>UFH</td><td>60–90′</td><td>↑ PTT</td><td>Protamine IV 1 mg/100 U UFH (max 50 mg). For infusions, dose to reverse 2× UFH given per h.</td></tr><tr><td>LMWH</td><td>2–7°</td><td>anti-Xa*</td><td>Protamine reverses ~60%. 1 mg per 1 mg enox.</td></tr><tr><td>Bivalirudin</td><td>25′</td><td>↑ PTT</td><td>Dialysis</td></tr><tr><td>Argatroban</td><td>45′</td><td>↑ PTT</td><td>? Dialysis</td></tr><tr><td>Warfarin</td><td>36°</td><td>↑ PT</td><td><code>No bleeding</code>: vit K 2.5 mg PO if INR >9, o/w no e/o clinical benefit (Blood Adv 2019;3:789)</td></tr><tr><td></td><td></td><td></td><td><code>Bleeding</code>: vit. K 10 mg IV + either 4F-PCC (KCentra, 25, 35, or 50 U/kg for INR 2–4, 4–6, or >6) or FFP 2–4 U IV q6–8h (slower, more volume)</td></tr></tbody></table><hr><p>Properties and Antidotes for Anticoagulants & Fibrinolytics</p><table><thead><tr><th>Fibrinolytic</th><th>t1/2</th><th>Labs</th><th>Rx for O/D w/ Serious Bleeding (+ d/c anticoag)</th></tr></thead><tbody><tr><td>Fibrinolytic</td><td>20′, LK</td><td>↓ fbgn</td><td>Cryo, FFP, ± tranexamic or aminocaproic acid</td></tr><tr><td>Rivaroxaban<br>Apixaban<br>Dabigatran</td><td>8–12°<br>K > L</td><td>↑ PT*<br>anti-Xa*</td><td><code>Andexanet alfa</code></td></tr><tr><td>Dabigatran</td><td>~12°</td><td>K</td><td>↑ PTT* Idarucizumab: mAb binds drug (NEJM 2017;377:431)</td></tr></tbody></table><pre><code>* Mode of excretion: 
    * K, kidney
    * L, liver 
    * RES, reticuloendothelial system
</code></pre><hr><a href=#andexanet-alfa-factor-xa-decoy-receptor><h2 id=andexanet-alfa-factor-xa-decoy-receptor><span class=hanchor arialabel=Anchor># </span>Andexanet alfa (factor Xa decoy receptor)</h2></a><p>reverse apixaban and rivaroxaban in patients with life-threatening or uncontrolled bleeding</p><ul><li>800 mg bolus (30 mg/min)</li><li>→ 8 mg/min infusion<ul><li>(½ of above if taking ½ dose DOAC or ≥8 hrs since last dose; NEJM 2019;380:1326);</li></ul></li><li>4F-PCC: prothrombin complex concentrate (FII, VII, IX, X; Protein C & S). if andexanet not available</li></ul><hr><p><img src=https://i.imgur.com/vjuYH8L.png width=auto alt=h:650></p><blockquote><p>Activated Protein C (APC)</p></blockquote><hr><a href=#the-end><h1 id=the-end><span class=hanchor arialabel=Anchor># </span>THE END</h1></a></article><hr><div class=page-end id=footer><div class=backlinks-container><h3>↩️ 反向連結</h3><ul class=backlinks><li>🤭沒有找到反向連結</li></ul></div><div><script async src=https://cdn.jsdelivr.net/npm/d3@6.7.0/dist/d3.min.js integrity="sha256-+7jaYCp29O1JusNWHaYtgUn6EhuP0VaFuswhNV06MyI=" crossorigin=anonymous></script><h3>🤯互動圖</h3><div id=graph-container></div><style>:root{--g-node:var(--secondary);--g-node-active:var(--primary);--g-node-inactive:var(--visited);--g-link:var(--outlinegray);--g-link-active:#5a7282}</style><script src=https://www.physician.tw/js/graph.2d9e48dbe7ea47c0ef1c58296ce14448.js></script></div></div><div><div id=disqus_thread></div><script type=application/javascript>window.disqus_config=function(){},function(){if(["localhost","127.0.0.1"].indexOf(window.location.hostname)!=-1){document.getElementById("disqus_thread").innerHTML="Disqus comments not available by default when the website is previewed locally.";return}var t=document,e=t.createElement("script");e.async=!0,e.src="//physician.disqus.com/embed.js",e.setAttribute("data-timestamp",+new Date),(t.head||t.body).appendChild(e)}()</script><noscript>Please enable JavaScript to view the <a href=https://disqus.com/?ref_noscript>comments powered by Disqus.</a></noscript><a href=https://disqus.com class=dsq-brlink>comments powered by <span class=logo-disqus>Disqus</span></a></div><div id=contact_buttons><footer><p>本網站是由 Hsieh-Ting Lin 以❤️ 用 <a href=https://github.com/jackyzha0/quartz>Quartz</a>這個酷東西種出來🪴 , © 2023</p><p><a href=https://www.buymeacoffee.com/htl.lizard><img src=https://cdn.buymeacoffee.com/buttons/v2/default-yellow.png width=200></a></p><ul><li><a href=https://www.physician.tw/>🏠首頁</a></li><li><a href=https://www.facebook.com/htlin.lizard>Facebook</a></li><li><a href=https://twitter.com/htlin222>Twitter</a></li><li><a href=https://github.com/htlin222>GitHub</a></li><li><a href=https://htlin.site>Blog</a></li><li><a href=https://htlin222.medium.com>Medium</a></li></ul></footer></div></div></body></html>